£162M
The financing was led by SoftBank Vision Fund 2 with participation from Novo Holdings and Blackrock to expand the proprietary drug pipeline.
"We believe Exscientia’s innovative use of AI to discover and design better quality drugs with greater efficiency has the potential to create important medicines faster than ever before. With the convergence of technology and biology, drug discovery is rapidly evolving in ways that will reshape the industry. The Exscientia team have been leaders in AI-based drug discovery since the field’s inception and we believe they will continue shaping its future."
SoftBank Vision Fund + 11 others